Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Healthtrust
Cipla
Argus Health
Teva
Chubb
Dow
Citi

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,723,338

« Back to Dashboard

Summary for Patent: 6,723,338
Title: Compositions and methods for treating lymphoma
Abstract:This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
Inventor(s): Sarris; Andreas H. (Houston, TX), Cabanillas; Fernando (Houston, TX), Logan; Patricia M. (Vancouver, CA), Burge; Clive T. R. (Brentwood Bay, CA), Goldie; James H. (Vancouver, CA), Webb; Murray S. (Delta, CA)
Assignee: Inex Pharmaceuticals Corporation (Burnaby, CA) Board of Regents, The University of Texas System (Austin, TX)
Application Number:09/541,436
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Device; Delivery;

Drugs Protected by US Patent 6,723,338

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Talon Therap MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,723,338

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,247,316 Compositions and methods for treating lymphoma ➤ Try a Free Trial
7,452,550 Liposomal antineoplastic drugs and uses thereof ➤ Try a Free Trial
7,887,836 Compositions and methods for treating lymphoma ➤ Try a Free Trial
7,060,828 Liposomal camptothecins and uses thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,723,338

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 309786 ➤ Try a Free Trial
Austria 309787 ➤ Try a Free Trial
Austria 442839 ➤ Try a Free Trial
Australia 2001270385 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Teva
US Army
Fuji
Cantor Fitzgerald
US Department of Justice
QuintilesIMS
Cipla
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.